Digital Therapeutics Market by Component (Devices, Software & Services), Application (Cardiovascular Disease, Central Nervous System Disorder, Chronic Respiratory Disease) - Global Forecast 2024-2030

[194 Pages Report] The Digital Therapeutics Market size was estimated at USD 6.42 billion in 2023 and expected to reach USD 8.05 billion in 2024, at a CAGR 26.42% to reach USD 33.16 billion by 2030.

Digital therapeutics, abbreviated as DTx, refers to a branch of digital health that encompasses a range of software-driven therapeutic interventions designed to prevent, manage, or treat a medical disorder or disease. Digital therapeutics are developed on the basis of clinical evidence and often undergo rigorous regulatory review. They are intended to be used independently or in conjunction with traditional medical treatments, and they provide patients, healthcare providers, and payers with data-driven, personalized approaches to enhance patient care and health outcomes. The digital therapeutics market is growing with the escalation of chronic diseases, rising healthcare costs, and advancements in healthcare technologies. Increasing smartphone penetration and the acceptance of telehealth services also contribute to the adoption of this technology. The demand for personalized and preventive healthcare solutions further strengthens the market's progress. However, the market faces considerable challenges, including regulatory hurdles, patient data security concerns, and the need for clinical validation of digital therapeutic applications. Amidst these challenges, the integration of digital therapeutics with electronic health records (EHRs) and the potential of AI and machine learning pave the way for innovation and the future growth of the digital therapeutics market.

Devices in digital therapeutics are often wearables, sensors, and other types of biomedical hardware that collect patient data. These devices can track a wide array of health metrics, such as physical activity, sleep patterns, and blood glucose levels. Need-based preference in devices leans towards user-friendliness, accuracy, and seamless integration with software applications. Software & services are seen as the core of digital therapeutics. This segment consists of platforms, applications, and professional services that deliver therapeutic interventions. Preference is given to scalability, interoperability, patient engagement, and data security of software and services.

Digital therapeutic solutions aimed at cardiovascular diseases often include applications that monitor heart rate, blood pressure, and cardiovascular health-related habits. Need-based preference for these solutions is high among patients with a history of heart disease and those at risk due to genetic factors or lifestyle. The central nervous system disorder application segment includes digital therapeutics for diseases including Parkinson's, Alzheimer's, depression, and ADHD. DTx solutions here aim at cognitive rehabilitation, behavior therapy, and medication management. Need-based preference is particularly strong among individuals seeking non-pharmacological interventions. Digital therapeutics in chronic respiratory diseases offer tools for asthma and COPD management, including inhaler tracking, symptom tracking, and environmental trigger alerts. These are preferred by patients needing continuous monitoring and those looking to manage disease exacerbations. Digital solutions for diabetes focus on blood glucose monitoring, insulin dosage tracking, and lifestyle coaching. Preference for diabetes management apps is high owing to the need for daily management and monitoring. Medication adherence applications of DTx aim to tackle the challenge of patients not taking their medications as prescribed. This need is ubiquitous across all patient categories but is particularly critical in the management of chronic diseases. Digital therapeutics for musculoskeletal disorders offer exercise programs, pain management techniques, and physical therapy guidance. They are highly preferred by patients seeking remote or supplemental treatment to traditional therapy. Digital therapeutic strategies for obesity include personalized nutrition, physical activity tracking, and behavior modification programs. The need in this segment is driven by the global rise in obesity rates and the associated health risks. Digital therapeutics for prediabetes focus on lifestyle interventions to prevent the onset of type 2 diabetes. These applications are useful for individuals identified as having prediabetes to delay or prevent disease progression. For smoking cessation, digital therapeutics include quit plans, tracking of progress, and counseling support. These tools have a high preference among those trying to quit smoking, often complementing nicotine replacement therapies.

In the Americas, the market for digital therapeutics is robust, underpinned by progressive regulatory frameworks, significant venture capital investments, and growing partnerships between DTx companies and healthcare providers. The United States Food and Drug Administration (FDA) has been creating a conducive environment for DTx products through clear guidance and approvals for prescription DTx, which are seen as important steps toward integrating these solutions into standard healthcare practices. Europe's digital therapeutics market is marked by a strong emphasis on evidence-based solutions and is driven by a diverse healthcare landscape where countries are adopting various approaches to integrate DTx into their healthcare systems. Initiatives such as Germany's Digital Healthcare Act (DVG), which allows doctors to prescribe digital health applications, exemplify the supportive regulatory environment. The Middle East and Africa, while still at nascent stages, are expected to witness growth, largely propelled by mobile-based health initiatives and partnerships aiming to improve access to healthcare services. The APAC region shows vast potential for digital therapeutics, although the market presents a heterogeneous mix of economic, cultural, and technological readiness. Countries, including Japan and Singapore, are at the forefront of adopting DTx, with favorable regulatory pathways and initiatives for digital health innovation. In other areas, such as India and China, rising smartphone penetration and government initiatives to support digital health ecosystems are creating opportunities for DTx expansion.

The FPNV Positioning Matrix is pivotal in evaluating the Digital Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Digital Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

• BehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics

  BehaVR and Fern Health have announced a strategic merger, forming RealizedCare, a digital care management platform focused on revolutionizing chronic pain treatment. As a convergence of pioneering digital therapeutic technology and traditional services, RealizedCare positions itself to overhaul value-based chronic pain management. By amalgamating BehaVR's expertise in creating validated immersive digital therapeutics and Fern Health's previously established chronic pain programs with industry leaders, RealizedCare aims to scale personalized interventions, bolstering outcomes and providing comprehensive support for pain management. [Published On: 2023-11-16]

• Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes

  Better Therapeutics, Inc., a company in the field of prescription digital therapeutics, announces the market introduction of AspyreRx, an innovative cognitive behavioral therapy application. This trailblazing digital tool, which holds FDA Class II authorization, is designed exclusively for adults grappling with type 2 diabetes (T2D). AspyreRx stands out as the initial app-based solution substantiated by rigorous randomized controlled trial data demonstrating significant, enduring reductions in A1c, with additional benefits including improved blood pressure, weight management, mood, and overall quality of life. [Published On: 2023-10-16]

• Lumanity Joins The Digital Therapeutics Alliance

  Lumanity has aligned with the Digital Therapeutics Alliance (DTA), a global non-profit organization dedicated to the progression of digital therapeutics (DTx). As a member of the DTA, Lumanity is set to contribute to the Alliance's fundamental vision of democratizing access to quality, evidence-backed digital therapy options for patients and stakeholders in the health sector. This partnership embodies the synergistic potential to elevate patient care by incorporating clinically proven digital therapies into conventional medical practice, championing both clinical excellence and healthcare economic improvement. [Published On: 2023-08-08]

The report delves into recent significant developments in the Digital Therapeutics Market, highlighting leading vendors and their innovative profiles. These include 2morrow Inc., Akili Interactive Labs, Inc., Ayogo Health Inc., Better Therapeutics, Inc., Big Health, Inc., Biofourmis Inc., Canary Health Technologies Inc., Click Therapeutics, Inc., Cognoa, Inc., DarioHealth Corp., Fern Health, Inc., Fitterfly Healthtech Private Limited, Happify, Inc., Headspace Inc., Kaia Health Software Inc., Lark Technologies, Inc., Lumanity Inc., MedRhythms, Noom, Inc., Omada Health Inc., Pear Therapeutics, Inc., Propeller Health by ResMed Corp., SilverCloud by American Well Corporation, Voluntis by AptarGroup, Inc., and Welldoc, Inc..

This research report categorizes the Digital Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Component
  • Devices
  • Software & Services
• Application
  • Cardiovascular Disease
  • Central Nervous System Disorder
  • Chronic Respiratory Disease
  • Diabetes
  • Medication Adherence
  • Musculoskeletal Disorder
  • Obesity
  • Prediabetes
  • Smoking Cessation

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

1. What is the market size and forecast of the Digital Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Digital Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Digital Therapeutics Market?
4. What is the market share of the leading vendors in the Digital Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Digital Therapeutics Market?